Interleukin-1 Beta (IL-1B) ELISA Kit
- Created on the 12 March, 2017.
INTENDED USE
Interleukin-1 beta ELISA kit is intended for detecting in vitro quantitative concentrations of interleukin-1 beta (IL-1β, IL-1b) present in human serum, plasma (citrate, EDTA, heparin) and cell culture supernatant samples. This assay has a minimum detection limit of < 0.15 pg/ml.
BACKGROUND
Interleukin-1 beta (IL-1β or IL-1b) has been strongly implicated in the pathogenesis of osteoporosis and high bone turnover, it is a potent stimulator of bone resorption. Early researchers even called IL-1 beta endogenous pyrogen since it was able to induce fever and contributed to the wasting of muscles (PIF or proteolysis inducing factor). Low levels of IL-1 beta have been reported in normal serum and IL-1 inhibitors that vary only in their degree of glycosylation have been described to bind to the IL-1 receptor. These inhibitors are structurally more similar to IL-1 beta and have been thought to play vital roles in regulating the action of IL-1 beta.
The cells that are known to express IL-1b include endothelial cells, natural killer (NK) cells, trophoblasts, astrocytes, osteoblasts, keratinocytes, adrenal cortical cells, Schwann cells, neutrophils, oligodendroglia, T cells plus fibroblasts, monocytes and macrophages, platelets and megakaryocytes. Interleukin-1β can cause nuclear export of a specific NCOR co-repressor complex, leading to the de-repression of a specific subset of nuclear factor-kappa-B (NFKB)-regulated genes. It is a prominent microglia-derived cytokine which can cause oligodendrocyte death in co-culture with astrocytes and microglia, but not in pure culture of oligodendrocytes by alone. Furthermore, co-operation of IL-1 beta and PDGFB can result in inducing contractile-to-synthetic phenotype modulation of human aortic smooth muscle cells in culture. Micro-environmental IL-1β is essential for invasiveness and in vivo angiogenesis of different tumor cells. This association with the disease can be used to explain the biologic properties of IL-1 beta, thereby making it an important pro-inflammatory cytokine and a powerful inhibitor of gastric acid secretion. The following interleukin-1 beta ELISA kit is suitable for many diagnostic applications.
SENSITIVITY
The minimum detection sensitivity level of IL-1 beta (IL-1β, IL-1b) using current human interleukin-1 beta ELISA kit was approximately 0.15 pg/ml. The dynamic range for this assay is 3.9 – 250 pg/ml.
REFERENCES
- Effect of interleukin 1β inhibition in cardiovascular disease. Curr Opin Lipidol. (2012) 23 (6): 548-53. Review. Qamar A. and Rader D.J.
- Interleukin-1 beta: a potential link between stress and the development of visceral obesity. BMC Physiol. (2012) 12: 8. Review. Speaker K.J. and Fleshner M.
- A critical role for interleukin-1β in the progression of autoimmune diseases. Int Immunopharmacol. (2013) 17 (3): 658-69. Review. Zhao R., et al.
- Targeting interleukin-1β for pain. CNS Neurol Disord Drug Targets. (2011) 10 (5): 571-5. Review. Pillarisetti S.
- The interleukin 1beta pathway in the pathogenesis of osteoarthritis. J Rheumatol. (2008) 35 (12): 2306-12. Review. Daheshia M. and Yao J.Q.
ADDITIONAL INFORMATION
- Full Name: Interleukin-1 Beta (IL-1B) ELISA Kit
- Reactivity: Human
- Sample Type: Serum, Plasma (EDTA, Heparin, Citrate), Cell Culture Supernatant
- Sensitivity: < 0.15 pg/ml
